// App-Quantinova.ai

69 : Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Researchers

Presenter

  • Hagop M. Kantarjian

Principal Investigators

  • Carlo Gambacorti-Passerini

  • Jorge E Cortes

  • Francois Guilhot

  • Luke Akard

  • Vaishali Doshi

  • Jeff H Lipton

  • Dmitri Pavlov

  • Karin Gogat

  • Ladan Duvillie

  • Mark Shapiro

Medical Centers

  • CHU Poitiers, Poitiers, France

  • Universitatsklinikum Aachen, RWTH Aachen, Germany

  • University of Milano-Bicocca, Monza, Italy

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • France

  • Germany

  • Italy

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved